Factor V Leiden and prothrombin 20210 G-A mutations in controls and in patients with thromboembolic events during pregnancy or the puerperium

被引：7

作者：

Mehmet Yilmazer

Gulay Kurtay

Murat Sonmezer

Nejat Akar

机构：

[1] Kocatepe Universitesi, Tip Fakultesi Hastanesi, Kadin Hast. ve Dogum Anabilim Dali

来源：

Archives of Gynecology and Obstetrics | 2003年 / 268卷 / 4期

关键词：

Factor V Leiden mutation; Pregnancy; Prothrombin 20210 G-A mutation; Thromboembolic disease;

D O I：

10.1007/s00404-002-0430-4

中图分类号：

学科分类号：

摘要：

Factor V Leiden and prothrombin 20210 G-A mutations are independent risk factors for venous thrombosis. We studied the frequency of these mutations in 35 patients who had thromboembolic events during pregnancy and puerperium, and in 32 women who had a history of uncomplicated pregnancy, delivered either vaginally or by cesarean section, and did not have a past history of thromboembolism. Factor V Leiden mutation was present in 7 patients (20%) in the study group. Of these 7 patients, 1 was homozygote, whereas the remaining 6 were heterozygote for the mutation. Prothrombin 20210 G-A mutation was present in 2 patients (5.7%) in the study group. In the control group none of the 32 patients was positive for the factor V Leiden and prothrombin 20210 G-A mutations. Our findings indicate that the factor V Leiden mutation is an important risk factor for thromboembolic disease during pregnancy or puerperium.

引用

页码：304 / 308

页数：4

共 34 条

[1]

Akar N., Akar E., Dalgin G., Sozuoz A., Omurlu K., Cin S., Frequency of factor V (1691 G-A) mutation in Turkish population, Thromb Haemost, 78, pp. 1528-1529, (1997)

[2]

Akar N., Misirlioglu M., Akar E., Avcu F., Yalcin A., Sozuoz A., Prothrombin gene 20210 G-A mutation in the Turkish population, Am J Hematol, 58, (1998)

[3]

Akar N., Et al., Effect of methylenetetrahydrofolate reductase 677 C-T, 1298 A-C, and 1317 T-C on factor 1691 mutation in Turkish deep vein thrombosis patients, Thromb Res, 97, pp. 163-167, (2000)

[4]

Bertina R.M., Koeleman B.P.C., Koster T., Rosendaal F.R., Dirven R.J., De Ronde H., Van der Velden P.A., Reitsma P.H., Mutation in the blood coagulation factor V associated with resistance to activated protein C, Nature, 369, pp. 64-67, (1994)

[5]

Blomback M., Changes in blood coagulation and fibrinolysis during pregnancy and the menstrual cycle: New methods for detecting the changes, Adv Contracept, 7, SUPPL. 3, pp. 259-272, (1991)

[6]

Bokarewa M.I., Bremme K., Blomback M., Arg-506-Gln mutation in factor V and risk of thrombosis during pregnancy, Br J Haematol, 92, pp. 473-478, (1996)

[7]

Bykowska K., Vertun-Baranowska B., Windyga J., Lopaciuk S., Prevalence of G20210A prothrombin gene mutation in Poland, Pol Arch Med Wewn, 104, pp. 729-733, (2000)

[8]

Dahlback B., New molecular insights in to the genetics of thrombophilia. Resistance to activated protein C caused by Arg 506 to Gln mutation factor V as a pathogenic risk factor for thrombosis, Thromb Haemost, 74, pp. 139-148, (1995)

[9]

Gandrille S., Alhenc-Gelas N., Aiach M., A rapid screening method for the factor V Arg 506-Gln mutation, Blood Coagul, 6, pp. 245-248, (1995)

[10]

Gerhardt A., Scharf R.G., Beckmann M.W., Struve S., Bender H.G., Pillny M., Sandmann W., Zotz R.B., Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and puerperium, N Engl J Med, 342, pp. 374-380, (2000)

← 1 2 3 4 →